Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
about
Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell TherapyAntigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 DiabetesInducing and Administering Tregs to Treat Human DiseaseDisrupted regulatory T cell homeostasis in inflammatory bowel diseasesProtocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studyAutoimmunity in 2015.Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseasesHuman and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 TherapyTherapeutic window of interleukin-2 for autoimmune diseases.Functional Modulation of Regulatory T Cells by IL-2.Prediction and prevention of type 1 diabetes: update on success of prediction and struggles at preventionImmune interventions to preserve β cell function in type 1 diabetesValidation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets.Progress and challenges for treating Type 1 diabetes.Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation.Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice.Stabilizing human regulatory T cells for tolerance inducing immunotherapy.Combinatorial drug delivery approaches for immunomodulation.Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets.Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.Beta-cell specific autoantibodies: Are they just an indicator of type 1 diabetes?Restoring regulation - IL-2 therapy in systemic lupus erythematosus.Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.Dying to protect: cell death and the control of T-cell homeostasis.Group 2 ILCs: A way of enhancing immune protection against human helminths?Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine.PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells.Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice.Unique Features of Pancreatic-Resident Regulatory T Cells in Autoimmune Type 1 Diabetes.Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation.The Future of Immunotherapy: A 20-Year Perspective.Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.Therapeutic potential of low-dose IL-2 in immune thrombocytopenia: An analysis of 3 cases.Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation.Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
P2860
Q26742101-4D9BD879-DB3C-4689-8530-CBBD3ADCB992Q26770386-B9E1DC79-5FE5-4F5B-8268-C980E9F479F6Q26772723-BF3410B3-8000-4FAF-BE56-E0895CC74589Q26774590-4F0F844A-71F5-42BF-9E34-41662A11F6C4Q28604189-C83D9FD3-9FBA-4909-9306-25C2943E69F1Q30248983-3EECC950-1B99-475A-BE29-0C6D3ED96C21Q33650813-60897CA9-622D-49D7-9520-88B569C0D308Q35426986-6CADE31B-C077-46BE-AE01-4ACF5C9D8044Q35630817-B09372E7-6B0C-486F-8B0E-EB7942C47C67Q35830699-92CE157A-262A-46BA-AD5D-8A817F63E467Q36117948-A2DF6DB4-E8AB-4849-AA45-437C691FFE99Q36520618-5B478252-6872-4723-970A-DC9571213954Q36685390-BC0833B1-F123-4EE1-AB66-A33D8F135847Q36995389-8BA2E214-DE8B-41A1-B90F-5A7FDFF35122Q37155737-5C8E1308-D204-4049-BF1D-1469BBAAEB16Q37377103-58D6FB20-45C6-424F-B7A0-9DD10EE59AFBQ38424758-10F4AD5E-EB8A-4742-9EF0-5C9D69605B11Q38576971-A9735B32-EF60-494E-B17E-CA8DF8D4F546Q38616032-87B0FBF6-E038-49A7-B73E-CAB6EA132DC9Q38644779-46142C74-6726-4C53-8A35-EC55B3E0BAE9Q38680602-ECB0CFA4-3211-4E3E-B8B5-B5F390167F1DQ38779612-9DEB6646-82F6-479B-BC03-199F73E00CFFQ38807853-968506F8-2949-4486-B446-4CB058E4D81EQ38818303-1D4752CD-E46B-4A82-9947-B08C15B6446BQ38860839-B3DD4636-DD37-45D5-A550-FA2F5DAF9032Q39076924-F8DC2154-40BF-48D3-AEC0-1F13087EEBD3Q39277476-290056E9-8675-4C91-8F3A-67BAC62C956FQ39381981-361CC77F-E9A9-49E2-B224-066FBE6342CCQ40122658-E9E5BA21-31C0-4CF7-8FC5-86D3B36FD1D5Q41140315-348E13FA-FDBC-4D56-ADB7-34BE7CA64412Q41205365-18C07FF3-F6DB-4A33-A35A-7574DEF55A4EQ41233136-F540D3AA-B69D-4C85-A03A-1C1B35F5EB40Q42369832-58D939A0-8C45-4771-AD7B-2F56B6FED8FAQ46268804-E544E6CA-8641-4721-9674-3895ABD26A02Q47162933-32EF418B-F2A1-426F-9872-C6819805F626Q47385058-8FB78775-7CA0-4ABC-BC81-8557A1435D01Q48282629-19CACC33-36EF-4DD5-8C8E-44496D20387CQ48554984-C8CC4518-7E3C-4232-83CC-A095F1D44BEAQ48668293-D5FC1D68-F717-4CC3-9D6D-28683189AB21Q48826007-376DEB93-62F2-456D-AA3B-C6EE7A6B5D68
P2860
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@en
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@nl
type
label
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@en
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@nl
prefLabel
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@en
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@nl
P2093
P50
P1476
Low-dose interleukin-2 fosters ...... tuned milieu in T1D patients.
@en
P2093
Agnès Hartemann
Alberto Pugliese
Georgia Afonso
Guillaume Churlaud
Jane H Buckner
Nicolas Dérian
Roberta Lorenzon
S Alice Long
Thomas R Malek
P356
10.1016/J.JAUT.2015.01.001
P577
2015-01-26T00:00:00Z